Building Momentum: Unleashing Small-Cap Potential (CLDI, DFLI, TNFA, DRMA, AMPG)

Uncovering the hidden potential of small-cap stocks can present lucrative opportunities for investors. These overlooked companies capitalize on key catalysts to drive their growth. In this article, we highlight five small-cap stocks, examining the drivers behind their momentum and increasing investor interest.

Calidi Biotherapeutics Inc. (NYSE: CLDI) - Calidi Biotherapeutics Inc. saw its shares rise 21% last week, closing at $0.75. In January, the company reported an ending cash balance of approximately $9.6 million as of December 31, 2024. Strengthened by recent fundraising efforts, including proceeds from its At-The-Market Offering Agreement (ATM), Calidi opted to terminate its Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., an affiliate of Yorkville Advisors, effective January 23, 2025. CEO and Chairman Allan Camaisa described this decision as a key milestone in the company’s financing strategy, emphasizing that the completion of recent fundraising efforts allows Calidi to focus on clinical and operational goals while eliminating a potential stock overhang. He reiterated the company's commitment to enhancing shareholder value and advancing its leadership in targeted systemic and localized antitumor virotherapies. Calidi continues to progress with its virotherapy platforms, recently achieving milestones such as the acceptance of an abstract on its systemic RTNova enveloped virotherapies for presentation at the American Association for Cancer Research (AACR) Annual Meeting in April 2025. Additionally, the FDA has granted IND clearance for a Northwestern University-led Phase 1b/2 trial of CLD-101 for high-grade gliomas, with enrollment expected to begin in the first quarter of 2025. The company is also inviting investors to a webinar on February 5, 2025, at 4:15 p.m. ET, hosted by RedChip Companies. Calidi’s CFO, Andrew Jackson, and CSO, Antonio F. Santidrian, PharmD, PhD, will discuss the company’s innovative cell-based delivery platforms, which are designed to protect, amplify, and potentiate oncolytic viruses for improved cancer treatment. The presentation will cover Calidi’s lead programs, including the CLD-400 systemic platform for metastatic cancers, CLD-201 for advanced solid tumors, and CLD-101 for high-grade gliomas, followed by a live Q&A session. As the company continues to provide updates, attention will remain on trading volume and a potential resistance break in the $0.84–$0.86 range.

--

Dragonfly Energy Holdings Corp. (NASDAQ: DFLI) - Dragonfly Energy Holdings Corp. saw its shares decline 5% last week, closing at $2.38. In December, the company announced a significant purchase order for its Battle Born® All-Electric APUs from Stevens Transport, Inc., one of North America's largest temperature-controlled freight carriers. This partnership marks another step in Stevens Transport’s commitment to leading the trucking industry in adopting advanced, environmentally sustainable transportation solutions. As a family-owned and operated full truckload carrier with operations across North America, Stevens Transport continues to invest in cutting-edge technology, efficiency, and sustainability. Following extensive testing and trials, the company has committed to transitioning its entire 2,500-truck fleet to Dragonfly Energy’s lithium power solutions. The transition will begin in the first quarter of 2025 with the installation of Battle Born All-Electric APUs in 100 trucks, continuing until the entire fleet is upgraded. This commitment positions Dragonfly Energy as a key technology partner in Stevens Transport’s sustainability efforts, supporting its goal of reducing carbon emissions, improving fuel efficiency, and setting a new standard for green initiatives in logistics. Wade Seaburg, chief revenue officer for Dragonfly Energy, emphasized that Stevens Transport’s decision highlights hybrid electrification as a practical next step for fleet sustainability. He noted that the All-Electric APU system is designed to provide tangible benefits, including lower emissions, cost savings, and improved driver comfort, reinforcing Dragonfly Energy’s role in driving the industry toward a more sustainable future. As we await further updates from the company, we will be watching for increased trading volume and a potential break above the $2.50 resistance level.

--

TNF Pharmaceuticals, Inc. (NASDAQ: TNFA) - TNF Pharmaceuticals, Inc. saw its shares decline 1% last week, closing at $0.88. In January, the company announced a key safety data milestone supporting expanded and longer-term clinical studies of its novel TNF-alpha (TNF-α) inhibitor, isomyosamine, across multiple indications. A recently completed FDA-recommended study confirmed the drug’s safety over 13 weeks of treatment at all evaluated dose levels. Mitchell Glass, M.D., President and Chief Medical Officer of TNFA, emphasized that the positive results reinforce isomyosamine’s strong safety profile and pave the way for extended clinical trials. He expressed confidence in the company’s ability to advance its comprehensive isomyosamine platform, particularly in a longer-term clinical trial for sarcopenia, as well as future studies targeting conditions linked to immunometabolic dysregulation. TNFA plans to initiate a Phase 2b clinical trial early in the first quarter of 2025 to further evaluate isomyosamine’s efficacy in treating sarcopenia, building on statistically significant positive results from a previous Phase 2 study. As the company continues to provide updates, attention will be on a potential uptrend and a resistance break at $0.96.

--

Dermata Therapeutics, Inc. (NASDAQ: DRMA) - Dermata Therapeutics, Inc. saw its shares rise 2% last week, closing at $1.23. In December, the company announced that the U.S. Food and Drug Administration (FDA) approved the proprietary name Xyngari (pronounced zin-gar-ee) for its Phase 3 acne drug candidate, formerly known as DMT310. The approval is contingent upon the successful submission and acceptance of a new drug application (NDA). Chairman, President, and CEO Gerry Proehl highlighted this as another significant milestone in the development of Xyngari. With Phase 3 topline results expected in March 2025 and a recent notice of allowance for a U.S. patent covering its use in acne treatment, he expressed confidence in Dermata’s ability to complete the development program and eventually file an NDA. Proehl emphasized the commercial potential of Xyngari, noting that if approved, it could become the first safe, effective, once-weekly topical treatment for acne. As the company moves forward, attention will be on increased trading volume and a potential break above the $1.28 resistance level.

--

Amplitech Group Inc. (NASDAQ: AMPG) - AmpliTech Group Inc. saw its shares rise nearly 1% last week, closing at $1.97. In January, the company announced that it had officially received a patent number from the United States Patent and Trademark Office (USPTO) following a previously issued Notice of Allowance for its optimized 5G Front End Technology. Additional formal patent certificates, also granted Notices of Allowance, are expected to be issued during the first quarter of fiscal year 2025. The company is working with intellectual property experts to assess the technology's valuation for prompt inclusion in its balance sheet. With the issuance of this patent, AmpliTech continues to strengthen its position as a leader in innovation, protecting proprietary technology that enhances the performance and efficiency of its 5G designs. CEO and CTO Fawad Maqbool emphasized the significance of this milestone, noting that it will add substantial value to the company’s intellectual property portfolio. He highlighted the company’s commitment to innovation and its ongoing efforts to drive shareholder value, particularly as more patents are expected in early 2025. AmpliTech also announced its participation in the upcoming Mobile World Congress (MWC) in Barcelona, where it will exhibit its latest ORAN 5G products at Booth 2C78. The company will showcase its high-speed MIMO 64T64R CAT B ORAN radio and private 5G network solutions while engaging with key industry players. In addition, AmpliTech will participate in Industry Day 25: Toward Open 6G Networks, an event hosted by the Institute for the Wireless Internet of Things at Northeastern University from February 3 to February 5, 2025, in Boston, Massachusetts. At MWC (March 3 – March 6, 2025), the premier global event for 5G connectivity and communication infrastructure, AmpliTech will connect with leading experts in 5G and the Metaverse. With over 80,000 attendees, the event will feature major exhibitors, including AT&T, Ericsson, Nokia, Samsung, and Tech Mahindra. AmpliTech will focus on promoting its MIMO 64T64R CAT B ORAN radio and its latest private 5G radio network products. As the company continues to provide updates, attention will be on a potential resistance break at $2.15.

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.